SABSW and SABS Related Headlines
Go Back- SAB Biotherapeutics reports Q1 2026 results, enrollment progress
- SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights
- SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET
- SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress
- SAB Biotherapeutics prices $85 million public offering at $3.85 per share
- SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
- SAB BIO reports Phase 1 data showing C-peptide preservation signals
- SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes
- SAB BIO Reports Full Year 2025 Financial Results and Business Highlights
- SAB BIO Highlights Data in Multiple Presentations at EASD
SABSW and SABS Related Press Releases
Go Back- SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights
- SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET
- SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress
- SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants
- SAB BIO Announces Additional Phase 1 Data for SAB-142 in Adult Patients with Established Autoimmune Type 1 Diabetes
- SAB BIO Reports Full Year 2025 Financial Results and Business Highlights
- SAB BIO Highlights Data in Multiple Presentations at EASD
